MSS only

Who we are

  • April 5, 2022
    Radiotherapy in Combination With Sintilimab,GM-CSF and Fruquintinib in Patients With MSS mCRC
  • April 5, 2022
    The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer
  • April 5, 2022
    A Study of NX-1607 in Adults With Advanced Malignancies
  • April 5, 2022
    REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors
  • April 5, 2022
    Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer
  • April 5, 2022
    CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
  • January 1, 1970
    Isunakinra Alone and in Combination with Pembrolizumab in Patients with Colorectal Cancer (MSS)
  • January 1, 1970
    GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
  • January 1, 1970
    A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab
  • January 1, 1970
    Regorafenib and Sintilimab in Combination With Electroacupuncture in MSS CRC